This chemical is primarily used in the development of Proteolysis Targeting Chimeras (PROTACs), which are innovative therapeutic molecules designed to degrade specific disease-causing proteins. Its application focuses on targeting HER3, a receptor involved in various cancers, particularly those resistant to conventional therapies. By binding to HER3, it facilitates the recruitment of E3 ubiquitin ligase, marking the protein for degradation by the proteasome. This approach offers a promising strategy for treating HER3-driven cancers, potentially overcoming resistance mechanisms and improving patient outcomes. Research and preclinical studies are ongoing to optimize its efficacy and explore its potential in targeted cancer therapies.